[A16-32] Elotuzumab - Benefit assessment according to §35a Social Code Book V
Last updated 01.12.2016
Project no.: A16-32
Commission: Commission awarded on 01.06.2016 by the Federal Joint Committee (G-BA).
Report type: Dossier assessment
Status: Commission completed
Department/Division: Drug Assessment
Topic: Cancer
Note:
After completion of the assessment by IQWiG the Federal Joint Committee (G-BA) conducts a commenting procedure. This may provide supplementary information and as a result lead to a modified benefit assessment. Further information and the decision on the early benefit assessment can be found on the relevant page of the G-BA website.
Federal Joint Committee (G-BA)
2016-12-01 A G-BA decision was published.